This 2 arm, randomized, open label study will evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy in patients with HER2 positive breast cancer who have residual tumor present in the breast or axillary lymph nodes following preoperative therapy <a href=http://stromectol.one>stromectol italia</a> There was no significant difference in age or BMI among the treatment groups
